However, not all patients respond well to immunotherapy, even though predictive biomarkers for immune checkpoint inhibitors (ICIs), such as PD-L1 expression, microsatellite instability, and tumor mutational burden, have been used in the clinic [4]. Here, CD274 is linked to neoplasm.